Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

By clinicaltrials.govJuly 23, 2026Updated:July 23, 2026No Comments1 Min Read